AKT/GSK-3 Pathway Targeting; Botanicals and Bioactive Compounds with Anticancer Activities

Atefeh Jalali1, Mohammad M Zarshenas1

  • 1Medicinal Plants Processing Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Abstract

Insights

Natural products show promise in cancer treatment by targeting the Akt/GSK-3 pathway. This review identifies 64 plants with anticancer activity, offering potential for new drug development against cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Signaling pathways, particularly the Akt/GSK-3 pathway, are frequently dysregulated in human cancers.
  • The Akt cascade influences cancer progression by regulating apoptosis, cell cycle, metabolism, and cell longevity.
  • GSK-3, downstream of Akt, plays a contrasting role in cancer development.

Purpose of the Study:

  • To review the efficacy of herbal medicines targeting the critical Akt/GSK-3 signaling pathway in cancer.
  • To identify potential natural products for novel anticancer drug development.

Main Methods:

  • Systematic literature search using keywords 'plant', 'natural', 'cancer', 'AKT', and 'GSK' in Scopus and Google Scholar databases up to August 30, 2020.
  • Collection and discussion of papers related to pharmacology, toxicology, and pharmaceutics of identified natural products.

Main Results:

  • The Akt/GSK-3 pathway is crucial in cancer progression.
  • Inhibition of Akt/GSK-3 in cancer cells leads to apoptosis, autophagy, anti-proliferation, growth inhibition, anti-metastasis, and anti-angiogenesis.
  • 64 plants or bioactive components demonstrating anticancer activity via the Akt/GSK-3 pathway were identified.

Conclusions:

  • The Akt/GSK-3 signaling pathway is a significant target for cancer therapy.
  • Natural products offer a promising avenue for developing anticancer drugs targeting this pathway.
  • Identified plants warrant further investigation in clinical trials, given the prevalence of cell-line based studies.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.4K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K